• The WHO’s Fair Pricing report fails to adequately understand global public interests in medicines like sofosbuvir, and the importance of Ramsey pricing in facilitating fair access to innovative medicines.

  • There are 12-14 million individuals across the world living with familial hypercholesterolemia (FH).   Today there are more opportunities than ever before for identifying and providing tailored treatments for FH and its consequences. With the growing prospect of treatments that address fundamental disease mechanisms there is now every reason to fight to increase rates of diagnosis.